Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
127.67
-0.73 (-0.57%)
Nov 12, 2024, 4:00 PM EST - Market closed
Ascendis Pharma Employees
Ascendis Pharma had 879 employees as of December 31, 2023. The number of employees increased by 82 or 10.29% compared to the previous year.
Employees
879
Change (1Y)
82
Growth (1Y)
10.29%
Revenue / Employee
$387,176
Profits / Employee
-$596,701
Market Cap
7.63B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 879 | 82 | 10.29% |
Dec 31, 2022 | 797 | 158 | 24.73% |
Dec 31, 2021 | 639 | 157 | 32.57% |
Dec 31, 2020 | 482 | 152 | 46.06% |
Dec 31, 2019 | 330 | 114 | 52.78% |
Dec 31, 2018 | 216 | 79 | 57.66% |
Dec 31, 2017 | 137 | 36 | 35.64% |
Dec 31, 2016 | 101 | 23 | 29.49% |
Dec 31, 2015 | 78 | 23 | 41.82% |
Dec 31, 2014 | 55 | 10 | 22.22% |
Dec 31, 2013 | 45 | 7 | 18.42% |
Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Grifols | 23,737 |
Bausch + Lomb | 13,300 |
Elanco Animal Health | 9,800 |
Jazz Pharmaceuticals | 2,800 |
Legend Biotech | 1,826 |
Cytokinetics | 423 |
Madrigal Pharmaceuticals | 376 |
Halozyme Therapeutics | 373 |
ASND News
- 6 weeks ago - Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency - GlobeNewsWire
- 6 weeks ago - New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024 - GlobeNewsWire
- 7 weeks ago - Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs - GlobeNewsWire
- 7 weeks ago - Ascendis Pharma A/S Announces Proposed Public Offering of ADSs - GlobeNewsWire
- 2 months ago - Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year - Benzinga
- 2 months ago - Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo - GlobeNewsWire
- 2 months ago - Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024 - GlobeNewsWire
- 2 months ago - Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults - GlobeNewsWire